CD274 and glioblastoma: The immunosuppressive tumor microenvironment of GBM, characterized by programmed death ligand-1 (PD-L1) overexpression, hinders effective T-cell-mediated anti-tumor responses and underlines the requirement for advanced immunotherapeutic strategies for treating GBM patients [3].